Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 1954-1965

  Christie, Lori Ann ^a   Acharya, Munjal M ^a   Parihar, Vipan K ^a   Nguyen, Anna ^a   Martirosian, Vahan ^a   Limoli, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEARNING; LOCOMOTION; MALE; MEMORY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OUTCOME ASSESSMENT; PLACE RECOGNITION TASK; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; TREATMENT DURATION; TUMOR XENOGRAFT; VISUAL MEMORY; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BREAST NEOPLASMS; BROMODEOXYURIDINE; COGNITION DISORDERS; CONDITIONING (PSYCHOLOGY); CYCLOPHOSPHAMIDE; DOXORUBICIN; FEAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; HUMANS; LEARNING; MALE; MEMORY; MOTOR ACTIVITY; NEUROGENESIS; NEURONS; RATS; RATS, NUDE;

EID: 84859396336     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2000     Document Type: Article

References (45)

1. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22:2233-9. (Pubitemid 41095159)
2. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-50. (Pubitemid 29075285)
3. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-701. (Pubitemid 30463551)
4. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-93. (Pubitemid 34072533)
5. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175-83. (Pubitemid 46606186)
6. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004;100:2292-9. (Pubitemid 38657875)
7. Myers JS. Chemotherapy-related cognitive impairment. Clin J Oncol Nurs 2009;13:413-21.
8. Joly F, Rigal O, Noal S, Giffard B. Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 2011;20:1251-8.
9. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7:192-201.
10. Monje M, Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res 2012;227:376-9.
11. Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 2011;50:1630-8.
12. Myers JS. The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol 2010;678:119-23.
13. Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol 1994;15:1267-73. (Pubitemid 24257853)
14. Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011;32:480-93.
15. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-11. (Pubitemid 46944511)
16. Myers JS. Neuropsychologic testing for chemotherapy-related cognitive impairment. Adv Exp Med Biol 2010;678:55-69.
17. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007;25:2455-63. (Pubitemid 46999217)
18. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-9. (Pubitemid 351461030)
19. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011;12:703-8.
20. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an indepth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 2009;3:223-32.
21. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs 2010;19:1362-70.
22. Vardy J, Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007;63:183-202. (Pubitemid 47126866)
23. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009;115:1776-83.
24. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-8.
25. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010;116:3348-56.
26. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 2010;22:48-54.
27. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011;35:729-41.
28. Reiriz AB, Reolon GK, Preissler T, Rosado JO, Henriques JA, Roesler R, et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006;12:5000; author reply 5000-1.
29. Yang M, Kim JS, Song MS, Kim SH, Kang SS, Bae CS, et al. Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits. Neurobiol Learn Mem 2010;93:487-94.
30. Lee GD, Longo DL, Wang Y, Rifkind JM, Abdul-Raman L, Mamczarz JA, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006;12:198-205. (Pubitemid 43166195)
31. Lyons L, Elbeltagy M, Bennett G, Wigmore P. The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat. PLoS One 2011;6:e21445.
32. Liedke PE, Reolon GK, Kilpp B, Brunetto AL, Roesler R, Schwartsmann G. Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 2009;94:239-43.
33. Sieklucka-Dziuba M, Saczonek J, Dziuba J, Kleinrok Z. Central action of somecytostatics-methotrexate (MTX) and doxorubicin (DXR). II. The influence on the seizure activity and the learning and memory processes in mice. Ann Univ Mariae Curie Sklodowska Med 1998;53:81-8.
34. Mumby DG, Gaskin S, Glenn MJ, Schramek TE, Lehmann H. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn Mem 2002;9:49-57. (Pubitemid 34507491)
35. Save E, Buhot MC, Foreman N, Thinus-Blanc C. Exploratory activity and response to a spatial change in rats with hippocampal or posterior parietal cortical lesions. Behav Brain Res 1992;47:113-27.
36. Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 1992;106:274-85.
37. Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development 2003;130:391-9. (Pubitemid 36175935)
38. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009;16:130-43.
39. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982;10:201-27. (Pubitemid 12044187)
40. Macleod JE, DeLeo JA, Hickey WF, Ahles TA, Saykin AJ, Bucci DJ. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007;181:168-72. (Pubitemid 46765012)
41. Saxe MD, Battaglia F, Wang JW, Malleret G, David DJ, Monckton JE, et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A 2006;103:17501-6. (Pubitemid 44788998)
42. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5:22.
43. Janelsins MC, Roscoe JA, Berg MJ, Thompson BD, Gallagher MJ, Morrow GR, et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 m. Cancer Invest 2010;28:544-53.
44. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94. (Pubitemid 29121971)
45. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 2006;23:127-39. (Pubitemid 44192385)